Shanghai Fosun Pharmaceutical (SHA:600196) secured the approval of China's drug administrator to conduct clinical trials for its CMC-2310 film.
CMC-2310 is an orally dissolving film used to treat schizophrenia in patients, according to a Monday filing with the Shanghai bourse.
Shares of the pharmaceutical company closed 2% higher Tuesday.